In May 2015, CoLucid Pharmaceuticals (Nasdaq: CLCD) completed a $55 million initial public offering. Our firm represented Boston-based CoLucid, completing the IPO in just three months.
CoLucid is a Phase 3 clinical-stage biopharmaceutical company that is developing an innovative and proprietary small molecule for the acute treatment of migraine headaches.
